Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report) rose 1.4% on Tuesday . The company traded as high as $59.98 and last traded at $59.79. Approximately 306,418 shares were traded during trading, an increase of 62% from the average daily volume of 189,291 shares. The stock had previously closed at $58.97.
Gemini Therapeutics Stock Down 3.0%
The stock has a market cap of $2.56 billion, a P/E ratio of -59.00 and a beta of -0.12. The firm has a 50 day simple moving average of $54.30 and a 200-day simple moving average of $51.47.
Gemini Therapeutics Company Profile
(
Get Free Report)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
Before you consider Gemini Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gemini Therapeutics wasn't on the list.
While Gemini Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
